Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

NCT07728383

RecruitingPhase 4

Sponsor: Gila Therapeutics, Inc.

Conditions: Obesity & Overweight

Interventions: Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet, Placebo liquid emulsion formulation

Countries: United States

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Body Mass Index 30 to 45

Exclusion Criteria:

* Type 2 Diabetes Mellitus
* Multiple Endocrine Neoplasia Type 2
* Medullary thyroid cancer
Locations (1)
  • Minneapolis, Minnesota, United States